To say the market has started the year off on the wrong foot is an understatement. This is especially true in the high beta NASDAQ growth names. The Nazzy is now off to the worst start to a year since 2008. Nervousness about the markets is evident. Both the VIX and VXN -or VIX of the NASDAQ- are near the…
Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product…
In regards to the likes of Amazon, the author of today’s article suggests that “the off-the-charts outperformance by its stock – and others like it – may be coming to an end” as a new market reality – wherein the tide shifts in favor of value stocks and away from growth stocks (which have outperformed for quite some time) –…
In today’s article the author reveals his best dividend stock picks for retirement income this year. The theme of this year’s picks is “Opposites Attract”, which he notes “implies that this collection of stocks might not have a lot in common with each other, but are in a good position to attract both growth and income for your retirement portfolio.”…
When it comes to building a healthy retirement portfolio, the authors of today’s article note that it’s important to have a mix of investments covering a variety of asset classes and industries – and to include both growth stocks and value stocks. They proceed to highlight three of the latter – value stocks – that may be ideal picks for…